Delivery Order 36F79718D0405-36C24924N0323
Award Date 3/1/24
Potential Completion Date 3/8/24
Potential Value $314K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Lawrenceville, Lawrence Township, NJ 08648, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs Veterans Health Administration awarded a delivery order contract to Bristol-Myers Squibb Company, doing business as Bristol-Myers Squibb, for the provision of ABECMA, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T immunotherapy. The $314,322.29 firm fixed price contract has a completion date of June 10, 2024 and is part of Bristol-Myers Squibb's Federal Supply Schedule contract for pharmaceuticals and drugs with the VA. This...
- Bristol-Myers Squibb Company has been awarded a delivery order valued at $335,042.65 by Veterans Integrated Service Network 9 for the supply of BREYANZI CAR T therapy to support the transplant center operations. This firm fixed-price delivery order, awarded on October 27, 2025, with an ultimate completion date of February 6, 2026, will be performed in Lawrenceville, New Jersey. The award carries no set-aside designation, reflecting Bristol-Myers Squibb's status as a large biopharmaceutical...
- This federal contract award to Bristol-Myers Squibb Company, a global biopharmaceutical company, is for the delivery of two chimeric antigen receptor (CAR) T cell therapies: BREYANZI and ABECMA. The therapies are being supplied to the U.S. Department of Veterans Affairs (VA) and its healthcare system, specifically to various Veterans Integrated Service Networks (VISNs). The contract, which has a firm fixed price of $314,322.29 and a completion date of February 12, 2025, is a delivery order under...
- This federal contract award is for the delivery of ABECMA, a chimeric antigen receptor (CAR) T cell therapy, to the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 9. The $314,322.29 firm fixed price delivery order was issued to Bristol-Myers Squibb Company, a global biopharmaceutical firm, under the company's existing Federal Supply Schedule (FSS) contract with the VA (Contract ID: 36F79724D0101). This FSS contract, with a $12,278,876,570.00 ceiling value,...
- This is a delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company for the provision of ABECMA, a chimeric antigen receptor (CAR) T cell therapy, for use in transplant injections. The contract has a firm fixed price of $338,932.84 and an ultimate completion date of May 17, 2025. The contract is a task order under Bristol-Myers Squibb's $12.28 billion Federal Supply Schedule (FSS) contract with the VA, which covers a wide range of drugs,...
- This is a firm fixed price delivery order contract awarded by the Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a global biopharmaceutical manufacturer. The contract, valued at $338,932.84, is for the supply of ABECMA INJECTION, a chimeric antigen receptor (CAR) T cell therapy used for the treatment of certain types of cancer, including non-Hodgkin lymphoma and multiple myeloma. The contract supports the VA's Veterans Health Administration in providing advanced medical...
- This is a delivery order awarded by the Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a global biopharmaceutical manufacturer. The $338,932.84 firm fixed-price order is for the ABECMA CAR T cell therapy, which is used to treat various types of cancer, including non-Hodgkin lymphoma and multiple myeloma. The contract is not set aside and is issued under Bristol-Myers Squibb's existing Federal Supply Schedule (FSS) contract with the VA, valued at $12,278,876,570.00 and...
- This federal contract award, valued at $314,322.29, is a delivery order issued by the U.S. Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a global biopharmaceutical firm. The contract is for the supply of IDECABTAGENE VICLEUCEL/ABECMA INJECTION, a chimeric antigen receptor (CAR) T-cell therapy used to treat certain types of cancer. The award is not designated as a set-aside contract. It is part of a larger Federal Supply Schedule (FSS) contract (ID: 36F79724D0101) between...
- This is a federal contract award to Bristol-Myers Squibb Company, a global biopharmaceutical company, for its BREYANZI chimeric antigen receptor (CAR) T cell therapy. The $310,935.67 firm fixed price delivery order was issued by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 9 and has an ultimate completion date of October 31, 2024. The award is not a set-aside contract. Bristol-Myers Squibb supplies the BREYANZI treatment, which is used to treat...
- This federal contract award was issued by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 9 (VISN 9) to Bristol-Myers Squibb Company, a global biopharmaceutical company, for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T-cell therapy used to treat non-Hodgkin lymphoma. The $310,953.67 firm fixed-price delivery order has an ultimate completion date of August 30, 2024. This award is a call against Bristol-Myers Squibb's existing Federal Supply Schedule...